Clinical Trial: A Phase II Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07647614) titled 'A Phase II Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease' on June 09.

Brief Summary: The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:

Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment?

Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (6...